Scholarlink

<p>Breast cancer is the most prevalent cancer among women and a leading cause of cancer-related deaths globally. Limitations of conventional therapies have prompted the development of advanced drug delivery systems, such as nanoparticles (NPs), to enhance therapeutic outcomes. In this study, leukocyte membrane-coated PLGA nanoparticles (LMc-DTX-CBD@NPs) were developed to deliver a combination of Docetaxel (DTX) and Cannabidiol (CBD) for targeted breast cancer therapy. The formulation was optimized using a central composite design, yielding particles with an average size of 146.4&#xa0;nm (uncoated) and 173.8&#xa0;nm (coated), with PDI values of 0.173 and 0.233, and zeta potentials of -10.64 mV and − 15.44 mV, respectively. SEM and TEM analyses confirmed smooth, spherical morphology, and XRD confirmed the crystalline nature of both drugs. High entrapment efficiencies were achieved (DTX: 97.79%, CBD: 89.64%) with a drug loading of 8.52 ± 0.05%. In-vitro studies demonstrated sustained drug release and &lt; 3% hemolysis, indicating good biocompatibility. The coated NPs were non-irritant, showing no vascular rupture. Stability studies confirmed formulation integrity, and in vitro cell line results demonstrated superior efficacy over conventional formulations. Overall, LMc-DTX-CBD@NPs present a promising strategy for targeted and effective breast cancer treatment.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Quality by Design Development of Leukocyte Membrane-coated Nanoparticles Co-loaded with Docetaxel and Cannabidiol for Targeted Breast Cancer Therapy

  • 期刊论文

  • 发表日期：

    2026年6月25日

查看全文
  • Saba Asif Qureshi,
  • Arif Nadaf,
  • Khalid Imtiyaz,
  • Mohd Moshahid Alam Rizvi,
  • Nazeer Hasan,
  • Farhan Jalees Ahmad

摘要

Breast cancer is the most prevalent cancer among women and a leading cause of cancer-related deaths globally. Limitations of conventional therapies have prompted the development of advanced drug delivery systems, such as nanoparticles (NPs), to enhance therapeutic outcomes. In this study, leukocyte membrane-coated PLGA nanoparticles (LMc-DTX-CBD@NPs) were developed to deliver a combination of Docetaxel (DTX) and Cannabidiol (CBD) for targeted breast cancer therapy. The formulation was optimized using a central composite design, yielding particles with an average size of 146.4 nm (uncoated) and 173.8 nm (coated), with PDI values of 0.173 and 0.233, and zeta potentials of -10.64 mV and − 15.44 mV, respectively. SEM and TEM analyses confirmed smooth, spherical morphology, and XRD confirmed the crystalline nature of both drugs. High entrapment efficiencies were achieved (DTX: 97.79%, CBD: 89.64%) with a drug loading of 8.52 ± 0.05%. In-vitro studies demonstrated sustained drug release and < 3% hemolysis, indicating good biocompatibility. The coated NPs were non-irritant, showing no vascular rupture. Stability studies confirmed formulation integrity, and in vitro cell line results demonstrated superior efficacy over conventional formulations. Overall, LMc-DTX-CBD@NPs present a promising strategy for targeted and effective breast cancer treatment.

Graphical Abstract